-
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
A Scoping Review of Resource Modeling in HTA Using Discrete Event Simulation
Sep 9, 2025, 16:22 PM -
Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards
Sep 9, 2025, 16:22 PM -
Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM -
Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models
Sep 9, 2025, 16:22 PM -
Balancing Rigor and Feasibility of Real-World Data Demands in Germany Within the EU HTA Context: How Fit for Purpose Is the Routine Practice Data Collection (Anwendungsbegleitende Datenerhebung, AbD)?
Sep 9, 2025, 16:22 PM -
What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland
Sep 9, 2025, 16:22 PM -
Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma: A Real-World Observational Study
Sep 9, 2025, 16:22 PM -
Integrating Stakeholder Insights Into Thematic Analysis: Enhancing Efficiency and Supporting HEOR
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Sep 9, 2025, 16:22 PM -
Importance of Decisional Context in the Health Technology Assessment (HTA) of Advanced Therapy Medicinal Products (ATMPs)
Sep 9, 2025, 16:22 PM -
Impact of Glucagon-Like Peptide-1 Treatments on Patient-Reported Outcomes in Type 2 Diabetes Mellitus
Sep 9, 2025, 16:22 PM -
Impact of CFTR Modulator Initiation on Direct Medical Costs for People With Cystic Fibrosis
Sep 9, 2025, 16:22 PM -
Resilient Pharmaceutical Supply Chains in Times of Crisis: A Comparative Analysis of Australia, France, Italy, Spain, and UK
Sep 9, 2025, 16:22 PM -
Analytical Modeling in Economic Evaluations of Obesity Interventions to Inform Health Policy: A Narrative Review
Sep 9, 2025, 16:22 PM -
Addressing the Impact of Alzheimer’s Disease on Care Capacity in the Netherlands: Implications for Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Bayesian Parametric Mixture Cure Survival Models With Delayed Treatment Effects and Application to Targeted Therapies in Advanced Ovarian Cancer
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India
Sep 9, 2025, 16:22 PM
